相关实验视频
Updated: Sep 15, 2025

08:51
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
9.2K
在多发性硬化症中研究抑郁症:关于临床表现,诊断和治疗的意大利德尔菲共识
Antonio Bruno1, Ettore Dolcetti1, Pietro Annovazzi2
1Neurology Unit - IRCCS Neuromed, Pozzilli (IS), Italy.
Frontiers in psychiatry
|July 15, 2025
概括
意大利专家就多发性硬化症 (MS) 抑郁症的诊断和治疗达成共识. 主要发现强调调整诊断标准,并将非药物治疗与抗抑郁药物相结合,以更好地照顾多发性硬化症患者.
科学领域:
- 神经学 神经学
- 精神病学是一个精神病学.
- 临床医学 临床医学
背景情况:
- 抑郁症是多发性硬化症 (MS) 的常见并发症,严重影响患者的生活质量和疾病进展.
- 在诊断和管理MS抑郁症的挑战源于重叠的症状和缺乏具体指导方针.
- 这项研究解决了在意大利背景下关于MS抑郁症的专家共识的需要.
研究的目的:
- 为了在意大利多发性硬化症 (MS) 专家之间达成共识.
- 定义MS患者抑郁症的临床表现,诊断标准和治疗策略.
- 为制定针对MS患者抑郁症管理的量身定制方法提供信息.
主要方法:
- 德尔菲在线调查与意大利各地的51名专家神经病学家进行了调查.
- 该调查包括35个问题,涵盖流行病学,临床特征,诊断和治疗MS抑郁症.
- 采用了两轮的共识过程,以匿名收集专家意见.
主要成果:
- 在所有陈述上都达到了完全的共识 (100%),其中90.6%达到了积极的共识.
- 证实了抑郁症和MS之间的强烈联系,抑郁症症状有时会在MS发作之前出现.
- 专家们同意将DSM-5标准适应MS特异性情绪障碍,并强调认知行为疗法 (CBT) 与抗抑郁药一起的重要性,同时指出对抗抑郁药疗效的担忧.
结论:
- 量身定制的诊断工具和综合治疗策略对于管理MS抑郁症至关重要.
- 需要进一步的研究来完善抗抑郁药的指导方针,并调查疾病修饰疗法 (DMT) 在治疗MS抑郁症中的作用.
- 这项研究强调了在多发性硬化症护理中对心理健康的综合方法的必要性.
相关概念视频
Depressive Disorders: MDD and Dysthymia
222
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
222
Depression: Overview
354
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
354
Depressive Disorders: Etiology
172
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
172
Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263
Antidepressant Drugs: MAOIs and Other Agents
372
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
372
Long-term Depression
31.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
31.5K

